REG - Theracryf PLC - Director/PDMR Shareholding

TheracryfAnnouncement

22/05/2025 12:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250522:nRSV8241Ja&default-theme=true

RNS Number : 8241J  Theracryf PLC  22 May 2025

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Director/PDMR Dealings

 

Alderley Park, UK - 22 May 2025: TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on neuropsychiatry and oncology confirms
that following a transfer on 21 May 2025, Northern Standard Limited, a company
that Non-Executive Director, Ed Wardle, has a 49 per cent interest in now owns
422,727,272 ordinary shares of 0.25 pence each in the Company ("Ordinary
Shares"). As a result, Mr Wardle is deemed to have a beneficial interest in
422,727,272 Ordinary Shares, representing 19.67 per cent. of the Company's
Ordinary Shares.

The Ordinary Shares were transferred by Tracarta Limited, of which Northern
Standard Limited is 51 per cent. owned a subsidiary. Following the above
transfer Tracarta Limited has no direct holding in the Company.

 

The notification set out below is provided in accordance with the requirements
of MAR.

                           Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
                           596/2014
 1                                               Details of the person discharging managerial responsibilities/person closely
                                                 associated
 a.  Name                                                              Mr Edward Wardle
 2   Reason for notification
 a.  Position/Status                                                   Non-Executive Director
 b.  Initial notification/                                             Initial Notification

     Amendment
 3                                               Details of the issuer, emission allowance market participant, auction
                                                 platform, auctioneer or auction monitor
 a.  Name                                                              TheraCryf plc
 b.  LEI                                                               213800NO3E6TSTQO8K20
 4                                               Details of the transaction(s): section to be repeated for (i) each type of
                                                 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                                                 place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument       Ordinary Shares of 0.25p each

Identification Code

                                                                       GB00BSVYN304

 b.  Nature of the transaction                                         Transfer of Ordinary Shares to Northern Standard Limited, a company that Ed
                                                                       Wardle has 49% ownership of.
 c.  Price(s) and volume(s)                                                              Price:  £0.0025

                                                                                         Volume: 422,727,272
 d.  Aggregated information                                             See above

     - Aggregated Volume

     - Price
 e.  Date of the transaction                                           21 May 2025
 f.  Place of the transaction                                          Outside a trading venue

 

Enquiries

 TheraCryf plc                                          +44 (0)1625 315 090

 Dr Huw Jones, CEO                                      enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO

 Turner Pope Investments (Joint Broker)                 +44 (0)20 3657 0050

 James Pope / Andy Thacker

 Cavendish Capital Markets (NOMAD & Joint Broker)       +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

 Vigo Consulting                                        +44 (0)20 7390 0231

 Rozi Morris                                            theracryf@vigoconsulting.com

 

About TheraCryf plc

TheraCryf is a clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C:/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAFSAAAFSEFA